User:Mr. Ibrahem/Mosunetuzumab

Mosunetuzumab, sold under the brand name Lunsumio, is a medication used to treat follicular lymphoma. Specifically it is used after other medications have failed. It is given by gradual injection into a vein.

Common side effects (≥20%) include cytokine release syndrome, fever, and headache. Other side effects may include immune effector cell-associated neurotoxicity syndrome (ICANS) and infections. Common laboratory abnormalities include decreased low neutrophils, low phosphate, high glucose, low lymphocytes, increased uric acid, low white blood cells, low hemoglobin, and low platelets. Use in pregnancy may harm the baby. It is a monoclonal antibody specifically a bispecific CD20-directed CD3 T-cell engager.

Mosunetuzumab was approved for medical use in Europe and the United States in 2022. It costs about 180,000 USD for the course of treatment in the United States as of 2023.